Multiomics
- We identify target candidates for new drugs in the central nervous system and develop synthetic medications.
- Utilizing transcriptomics, proteomics, lipidomics, and metabolomics.
RNA therapeutics
- Our goal is to enter clinical trials with RNA particle treatments capable of selectively delivering microglia without a carrier.
- Focused on mRNA therapy.
Drug repositioning and synthesis
- We are committed to drug repositioning, combination therapies, and derivative synthesis to accelerate new drug approvals and benefit patients
New disease models
- We develop specific animal models and patient-based cell models.
- Patient-based brain organoids with microglia, iPSC-derived microglia, and genetically engineered animal models.
